Management of Urinary Incontinence and Overactive Bladder - A Global Overview

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-06-14

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Although there are many marketed treatments for overactive bladder, there are few available for stress urinary incontinence or interstitial cystitis. Furthermore, despite available treatments for overactive bladder, many are associated with side effects leading to poor treatment compliance. With significant unmet needs remaining in these markets, there are clear opportunities for new entrants.


Scope

  • Overview of epidemiology, presentation and referral patterns, and diagnostic assessment for UUI, SUI, MUI, dry OAB, and IC
  • Role and use of non-pharmacological versus pharmacological treatment for UUI, SUI, MUI, dry OAB, and IC
  • Influences on treatment choice and perception of current drug therapies including tolterodine, oxybutynin, darifenacin, solifenacin and duloxetine
  • Evaluation of unmet needs and future outlook including awareness of the R&D drug pipeline


    • Report Highlights
    Drug therapy for urinary disorders has predominantly focused on the overactive bladder market - particularly urge urinary incontinence (UUI). However, as the UUI market becomes increasingly crowded, product differentiation is key. By focusing on the urgency and frequency symptoms, companies may be able to tap into an under-served market niche.

    Stress urinary incontinence (SUI) is considered the most common subtype of urinary incontinence, but poor awareness and limited treatment options have impacted presentation, diagnosis and treatment rates. The recent approval of duloxetine in the EU presents physicians with a much-needed treatment alternative, but uptake has been slow.

    Poor understanding of the underlying causes of interstitial cystitis (IC) have made diagnosis, management and development of effective drugs for this disorder difficult. With many physicians resorting to treatments that are not specifically approved for IC, experts in the field believe that this could be leading to suboptimal treatment outcomes.


    Reasons to Purchase

  • Forecast product sales by understanding key aspects of epidemiology, diagnosis and treatment
  • Gain a better understanding of the challenges facing current and future players in the overactive bladder and urinary incontinence market
  • Identify physicians' key concerns including unmet needs and the attributes that physicians believe are desirable for future treatments

    • Table of Contents

    Other users found this report page using the following search terms: incontinence overactive bladder urge incontinence stress incontinence indevus Sanctura bladder overactive incontinence oab urinary management market presentation pharmacological development

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.